was performed on nontraining patches and on
melanoma patient samples from The Cancer
Genome Atlas (TCGA), processed with the same
pipeline. Additional and more detailed mate-
rials and methods are available in the supple-
mentary materials ( 30 ).
REFERENCESANDNOTES
- L. A. Garraway, E. S. Lander, Lessons from the cancer genome.
Cell 153 , 17–37 (2013). doi:10.1016/j.cell.2013.03.002;
pmid: 23540688 - B. Vogelsteinet al., Cancer genome landscapes.Science 339 ,
1546 – 1558 (2013). doi:10.1126/science.1235122; pmid: 23539594 - S. Turajlicet al., Tracking Cancer Evolution Reveals
Constrained Routes to Metastases: TRACERx Renal.Cell 173 ,
581 – 594.e12 (2018). doi:10.1016/j.cell.2018.03.057;
pmid: 29656895 - J. Z. Sanbornet al., Phylogenetic analyses of melanoma reveal
complex patterns of metastatic dissemination.Proc. Natl.
Acad. Sci. U.S.A. 112 , 10995–11000 (2015). doi:10.1073/
pnas.1508074112; pmid: 26286987 - J. M. Zaretskyet al., Mutations Associated with Acquired
Resistance to PD-1 Blockade in Melanoma.N. Engl. J. Med. 375 ,
819 – 829 (2016). doi:10.1056/NEJMoa1604958; pmid: 27433843 - G. Cirielloet al., Emerging landscape of oncogenic signatures
across human cancers.Nat. Genet. 45 , 1127–1133 (2013).
doi:10.1038/ng.2762; pmid: 24071851 - M. Imielinskiet al., Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing.Cell 150 , 1107–1120 (2012).
doi:10.1016/j.cell.2012.08.029; pmid: 22980975 - E. Hodiset al., A landscape of driver mutations in melanoma.
Cell 150 , 251–263 (2012). doi:10.1016/j.cell.2012.06.024;
pmid: 22817889 - M. Ghandiet al., Next-generation characterization of the
Cancer Cell Line Encyclopedia.Nature 569 , 503–508 (2019).
doi:10.1038/s41586-019-1186-3; pmid: 31068700 - M. J. Garnettet al., Systematic identification of genomic markers of
drug sensitivity in cancer cells.Nature 483 , 570–575 (2012).
doi:10.1038/nature11005; pmid: 22460902 - J. Barretinaet al., The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity.Nature 483 ,
603 – 607 (2012). doi:10.1038/nature11003; pmid: 22460905 - L. Conget al., Multiplex genome engineering using CRISPR/
Cas systems.Science 339 , 819–823 (2013). doi:10.1126/
science.1231143; pmid: 23287718 - P. Maliet al., RNA-guided human genome engineering via Cas9.
Science 339 , 823–826 (2013). doi:10.1126/science.1232033;
pmid: 23287722 - J. Drostet al., Sequential cancer mutations in cultured human
intestinal stem cells.Nature 521 , 43–47 (2015). doi:10.1038/
nature14415; pmid: 25924068 - M. Matanoet al., Modeling colorectal cancer using CRISPR-Cas9-
mediated engineering of human intestinal organoids.Nat. Med. 21 ,
256 – 262 (2015). doi:10.1038/nm.3802; pmid: 25706875 - R. Alkallaset al., Multi-omic analysis reveals significantly
mutated genes and DDX3X as a sex-specific tumor suppressor
in cutaneous melanoma.Nat. Can. 1 , 635–652 (2020).
doi:10.1038/s43018-020-0077-8; pmid: 35121978 - B. C. Bastian, The molecular pathology of melanoma:
An integrated taxonomy of melanocytic neoplasia.Annu. Rev.
Pathol. 9 , 239–271 (2014). doi:10.1146/annurev-pathol-
012513-104658; pmid: 24460190 - A. H. Shainet al., The Genetic Evolution of Melanoma from
Precursor Lesions.N. Engl. J. Med. 373 , 1926–1936 (2015).
doi:10.1056/NEJMoa1502583; pmid: 26559571 - D. C. Bennett, Genetics of melanoma progression: The rise and
fall of cell senescence.Pigment Cell Melanoma Res. 29 ,
122 – 140 (2016). doi:10.1111/pcmr.12422; pmid: 26386262 - E. Hodis, L. A. Garraway, inMelanoma, D. E. Fisher, B. C. Bastian,
Eds. (Springer, 2017), vol. 161, pp. 1–23. - F. W. Huanget al., Highly recurrent TERT promoter mutations
in human melanoma.Science 339 , 957–959 (2013).
doi:10.1126/science.1229259; pmid: 23348506 - S. Hornet al., TERT promoter mutations in familial and
sporadic melanoma.Science 339 , 959–961 (2013).
doi:10.1126/science.1230062; pmid: 23348503 - M. Krauthammeret al., Exome sequencing identifies
recurrent somatic RAC1 mutations in melanoma.
Nat. Genet. 44 , 1006–1014 (2012). doi:10.1038/ng.2359;
pmid: 22842228
24. R. Akbaniet al., Genomic Classification of Cutaneous Melanoma.
Cell 161 , 1681–1696 (2015). doi:10.1016/j.cell.2015.05.044;
pmid: 26091043
25. L. B. Alexandrovet al., Signatures of mutational processes in
human cancer.Nature 500 , 415–421 (2013). doi:10.1038/
nature12477; pmid: 23945592
26. A. H. Shain, B. C. Bastian, From melanocytes to melanomas.
Nat. Rev. Cancer 16 , 345–358 (2016). doi:10.1038/
nrc.2016.37; pmid: 27125352
27. A. H. Shainet al., Genomic and Transcriptomic
Analysis Reveals Incremental Disruption of Key Signaling
Pathways during Melanoma Evolution.Cancer Cell
34 , 45–55.e4 (2018). doi:10.1016/j.ccell.2018.06.005;
pmid: 29990500
28. H. Zenget al., Bi-allelic Loss of CDKN2A Initiates Melanoma
Invasion via BRN2 Activation.Cancer Cell 34 , 56–68.e9 (2018).
doi:10.1016/j.ccell.2018.05.014; pmid: 29990501
29. M. R. Stratton, P. J. Campbell, P. A. Futreal, The cancer
genome.Nature 458 , 719–724 (2009). doi:10.1038/
nature07943; pmid: 19360079
30. Materials, methods, and supplementary text are available as
supplementary materials.
31. D. P. Deveret al., CRISPR/Cas9b-globin gene targeting in
human haematopoietic stem cells.Nature 539 , 384– 389
(2016). doi:10.1038/nature20134; pmid: 27820943
32. A. Hendelet al., Chemically modified guide RNAs enhance
CRISPR-Cas genome editing in human primary cells.
Nat. Biotechnol. 33 , 985–989 (2015). doi:10.1038/nbt.3290;
pmid: 26121415
33. S. C. Knightet al., Dynamics of CRISPR-Cas9 genome
interrogation in living cells.Science 350 , 823–826 (2015).
doi:10.1126/science.aac6572; pmid: 26564855
34. I. Yehet al., Combined activation of MAP kinase pathway
andb-catenin signaling cause deep penetrating nevi.
Nat. Commun. 8 , 644 (2017). doi:10.1038/s41467-017-
00758-3; pmid: 28935960
35. M. Stoeckiuset al., Cell Hashing with barcoded antibodies
enables multiplexing and doublet detection for single cell
genomics.Genome Biol. 19 , 224 (2018). doi:10.1186/s13059-
018-1603-1; pmid: 30567574
36. D. Kotliaret al., Identifying gene expression programs of
cell-type identity and cellular activity with single-cell
RNA-Seq.eLife 8 , e43803 (2019). doi:10.7554/eLife.43803;
pmid: 31282856
37. M. De Ceccoet al., L1 drives IFN in senescent cells and
promotes age-associated inflammation.Nature 566 , 73– 78
(2019). doi:10.1038/s41586-018-0784-9; pmid: 30728521
38. S. Wanget al., Interferon-ginduces senescence in normal
human melanocytes.PLOS ONE 9 , e93232 (2014).
doi:10.1371/journal.pone.0093232; pmid: 24681574
39. A. Rufini, P. Tucci, I. Celardo, G. Melino, Senescence and aging:
The critical roles of p53.Oncogene 32 , 5129–5143 (2013).
doi:10.1038/onc.2012.640; pmid: 23416979
40. Z. Liuet al., Telomerase reverse transcriptase promotes
epithelial-mesenchymal transition and stem cell-like traits in
cancer cells.Oncogene 32 , 4203–4213 (2013). doi:10.1038/
onc.2012.441; pmid: 23045275
41. Y. Wuet al., Telomerase reverse transcriptase mediates EMT
through NF-kB signaling in tongue squamous cell carcinoma.
Oncotarget 8 , 85492–85503 (2017). doi:10.18632/
oncotarget.20888; pmid: 29156735
42. A. Hodorogeaet al., Epithelial-Mesenchymal Transition
in Skin Cancers: A Review.Anal. Cell. Pathol. (Amst.)
2019 , 3851576 (2019). doi:10.1155/2019/3851576;
pmid: 31934531
43. W. E. Damskyet al.,b-catenin signaling controls metastasis in
Braf-activated Pten-deficient melanomas.Cancer Cell 20 , 741– 754
(2011). doi:10.1016/j.ccr.2011.10.030; pmid: 22172720
44. G. S. Kinkeret al., Pan-cancer single-cell RNA-seq identifies
recurring programs of cellular heterogeneity.Nat. Genet. 52 ,
1208 – 1218 (2020). doi:10.1038/s41588-020-00726-6;
pmid: 33128048
45. M. R. Webster, A. T. Weeraratna, A Wnt-er migration: The confusing
role ofb-catenin in melanoma metastasis.Sci. Signal. 6 , (2013).
doi:10.1126/scisignal.2004114; pmid: 2004114
46. W. E. Damsky, N. Theodosakis, M. Bosenberg, Melanoma
metastasis: New concepts and evolving paradigms.Oncogene 33 ,
2413 – 2422 (2014). doi:10.1038/onc.2013.194; pmid: 23728340
47. A. Kaur, M. R. Webster, A. T. Weeraratna, In the Wnt-er of life:
Wnt signalling in melanoma and ageing.Br. J. Cancer 115 ,
1273 – 1279 (2016). doi:10.1038/bjc.2016.332; pmid: 27764844
48. L. A. Garrawayet al., Integrative genomic analyses identify
MITF as a lineage survival oncogene amplified in malignant
melanoma.Nature 436 , 117–122 (2005). doi:10.1038/
nature03664; pmid: 16001072- I. Tiroshet al., Dissecting the multicellular ecosystem of metastatic
melanoma by single-cell RNA-seq.Science 352 , 189–196 (2016).
doi:10.1126/science.aad0501; pmid: 27124452 - M. Lauss, J. Nsengimana, J. Staaf, J. Newton-Bishop, G. Jönsson,
Consensus of Melanoma Gene Expression Subtypes Converges
on Biological Entities.J. Invest. Dermatol. 136 , 2502–2505 (2016).
doi:10.1016/j.jid.2016.05.119; pmid: 27345472 - L. Jerby-Arnonet al., A Cancer Cell Program Promotes T Cell
Exclusion and Resistance to Checkpoint Blockade.Cell 175 ,
984 – 997.e24 (2018). doi:10.1016/j.cell.2018.09.006;
pmid: 30388455 - S. Davidsonet al., Single-Cell RNA Sequencing Reveals a
Dynamic Stromal Niche That Supports Tumor Growth.
Cell Rep. 31 , 107628 (2020). doi:10.1016/
j.celrep.2020.107628; pmid: 32433953 - T. O. Jensenet al., Intratumoral neutrophils and plasmacytoid
dendritic cells indicate poor prognosis and are associated
with pSTAT3 expression in AJCC stage I/II melanoma.
Cancer 118 , 2476–2485 (2012). doi:10.1002/cncr.26511;
pmid: 21953023 - B. Johnstonet al., Chronic inflammation upregulates chemokine
receptors and induces neutrophil migration to monocyte
chemoattractant protein-1.J. Clin. Invest. 103 , 1269–1276 (1999).
doi:10.1172/JCI5208; pmid: 10225970 - R. Zilioniset al., Single-Cell Transcriptomics of Human and
Mouse Lung Cancers Reveals Conserved Myeloid Populations
across Individuals and Species.Immunity 50 , 1317–1334.e10
(2019). doi:10.1016/j.immuni.2019.03.009; pmid: 30979687 - A. M. De Silva, A. Gallardo, D. A. Fraser, Macrophage
production and activity of innate immune proteins C1q, C1r,
and C1s are modulated in response to molecular patterns.
J. Immunol. 204 , 226 (2020). - D. Fraser, E. Melzer, A. Camacho, M. Gomez, Macrophage
production of innate immune protein C1q is associated with M2
polarization (INM1P.434).J. Immunol. 194 , 56 (2015). - F.-C. Chou, H.-Y. Chen, C.-C. Kuo, H.-K. Sytwu, Role of Galectins
in Tumors and in Clinical Immunotherapy, Role of Galectins in
Tumors and in Clinical Immunotherapy,Int. J. Mol. Sci. 19 , 430
(2018). doi:10.3390/ijms19020430; pmid: 29389859 - K. Nazeri, A. Aminpour, M. Ebrahimi, "Two-stage convolutional
neural network for breast cancer histology image
classification" inLecture Notes in Computer Science,
B. ter Haar Romeny, A. Campilho, F. Karray, Eds. (Springer,
2018), vol. 10882, pp. 717–726. - J. N. Katheret al., Pan-cancer image-based detection of
clinically actionable genetic alterations.Nat. Can. 1 , 789– 799
(2020). doi:10.1038/s43018-020-0087-6; pmid: 33763651 - Y. Fuet al., Pan-cancer computational histopathology reveals
mutations, tumor composition and prognosis.Nat. Can. 1 ,
800 – 810 (2020). doi:10.1038/s43018-020-0085-8;
pmid: 35122049 - O. Shalemet al., Genome-scale CRISPR-Cas9 knockout
screening in human cells.Science 343 , 84–87 (2014).
doi:10.1126/science.1247005; pmid: 24336571 - T. Wang, J. J. Wei, D. M. Sabatini, E. S. Lander, Genetic screens in
human cells using the CRISPR-Cas9 system.Science 343 , 80– 84
(2014). doi:10.1126/science.1246981; pmid: 24336569 - H. Koike-Yusa, Y. Li, E.-P. Tan, Mdel. C. Velasco-Herrera,
K. Yusa, Genome-wide recessive genetic screening in mammalian
cells with a lentiviral CRISPR-guide RNA library.Nat. Biotechnol. 32 ,
267 – 273 (2014). doi:10.1038/nbt.2800; pmid: 24535568 - L. A. Gilbertet al., Genome-Scale CRISPR-Mediated Control of
Gene Repression and Activation.Cell 159 , 647–661 (2014).
doi:10.1016/j.cell.2014.09.029; pmid: 25307932 - A. Dixitet al., Perturb-Seq: Dissecting Molecular Circuits with
Scalable Single-Cell RNA Profiling of Pooled Genetic Screens.
Cell 167 , 1853–1866.e17 (2016). doi:10.1016/j.cell.2016.11.038;
pmid: 27984732 - D. A. Jaitinet al., Dissecting Immune Circuits by Linking
CRISPR-Pooled Screens with Single-Cell RNA-Seq.Cell 167 ,
1883 – 1896.e15 (2016). doi:10.1016/j.cell.2016.11.039;
pmid: 27984734 - C. Lee, J.-S. Kim, T. Waldman, Activated PI3K signaling as an
endogenous inducer of p53 in human cancer.Cell Cycle 6 ,
394 – 396 (2007). doi:10.4161/cc.6.4.3810; pmid: 17329971 - AACR Project GENIE Consortium, AACR Project GENIE:
Powering Precision Medicine through an International
Consortium.Cancer Discov. 7 , 818–831 (2017). doi:10.1158/
2159-8290.CD-17-0151; pmid: 28572459 - D. B. Johnsonet al., Acquired BRAF inhibitor resistance:
A multicenter meta-analysis of the spectrum and frequencies,
Hodiset al.,Science 376 , eabi8175 (2022) 29 April 2022 13 of 14
RESEARCH | RESEARCH ARTICLE